MX2023004794A - Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. - Google Patents
Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias.Info
- Publication number
- MX2023004794A MX2023004794A MX2023004794A MX2023004794A MX2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- autoimmune disease
- treat autoimmune
- treat
- vib551
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107182P | 2020-10-29 | 2020-10-29 | |
| US202163143541P | 2021-01-29 | 2021-01-29 | |
| US202163178286P | 2021-04-22 | 2021-04-22 | |
| PCT/US2021/057443 WO2022094334A1 (en) | 2020-10-29 | 2021-10-29 | Use of an anti-cd19 antibody to treat autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004794A true MX2023004794A (es) | 2023-09-15 |
Family
ID=81384348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004794A MX2023004794A (es) | 2020-10-29 | 2021-10-29 | Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287114A1 (https=) |
| EP (1) | EP4237447A4 (https=) |
| JP (1) | JP2023549075A (https=) |
| KR (1) | KR20230097118A (https=) |
| AU (1) | AU2021368769A1 (https=) |
| CA (1) | CA3197022A1 (https=) |
| IL (1) | IL302294A (https=) |
| MX (1) | MX2023004794A (https=) |
| TW (1) | TW202233676A (https=) |
| WO (1) | WO2022094334A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023534916A (ja) * | 2020-06-30 | 2023-08-15 | ビエラ バイオ インコーポレイテッド | 視神経脊髄炎スペクトラム障害を治療する方法 |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| MX2021012870A (es) * | 2019-04-24 | 2022-01-18 | Viela Bio Inc | Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias. |
| JP2023534916A (ja) * | 2020-06-30 | 2023-08-15 | ビエラ バイオ インコーポレイテッド | 視神経脊髄炎スペクトラム障害を治療する方法 |
-
2021
- 2021-10-29 JP JP2023526226A patent/JP2023549075A/ja active Pending
- 2021-10-29 CA CA3197022A patent/CA3197022A1/en active Pending
- 2021-10-29 EP EP21887669.6A patent/EP4237447A4/en active Pending
- 2021-10-29 IL IL302294A patent/IL302294A/en unknown
- 2021-10-29 AU AU2021368769A patent/AU2021368769A1/en active Pending
- 2021-10-29 WO PCT/US2021/057443 patent/WO2022094334A1/en not_active Ceased
- 2021-10-29 MX MX2023004794A patent/MX2023004794A/es unknown
- 2021-10-29 TW TW110140391A patent/TW202233676A/zh unknown
- 2021-10-29 KR KR1020237018007A patent/KR20230097118A/ko active Pending
-
2023
- 2023-04-19 US US18/303,303 patent/US20230287114A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4237447A1 (en) | 2023-09-06 |
| KR20230097118A (ko) | 2023-06-30 |
| IL302294A (en) | 2023-06-01 |
| EP4237447A4 (en) | 2024-07-17 |
| WO2022094334A1 (en) | 2022-05-05 |
| JP2023549075A (ja) | 2023-11-22 |
| TW202233676A (zh) | 2022-09-01 |
| AU2021368769A9 (en) | 2024-05-30 |
| CA3197022A1 (en) | 2022-05-05 |
| US20230287114A1 (en) | 2023-09-14 |
| AU2021368769A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020219743A3 (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| PH12020551970A1 (en) | Anti-muc1 antibody | |
| MX2021010441A (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. | |
| EA200970556A1 (ru) | Моноклональные антитела против angptl3 | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| MX2022015133A (es) | Anticuerpo humanizado anti-receptor de igf-1. | |
| PE20100251A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| MX2023004794A (es) | Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. | |
| JOP20190002A1 (ar) | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| JOP20210169A1 (ar) | أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري | |
| WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| WO2020247929A8 (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| EA200701452A1 (ru) | Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4) | |
| MX2021015882A (es) | Fragmentos de unión a antígeno egfr y composiciones que los comprenden. | |
| PH12022552725A1 (en) | Anti-ox40 antibody and uses thereof | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| NZ778430A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| MX2023010567A (es) | Variantes de anticuerpos no activadoras. | |
| ZA202305429B (en) | Antibody for tetanus toxin and use thereof |